BioPharma Dive November 16, 2025
The latest fund will mostly support biotechs making new drugs, with investments spanning from initial financings to follow-on rounds.
Sofinnova Partners, a European venture capital firm, said Monday it raised 650 million euros, or $750 million, for a new fund that will support up-and-coming life sciences companies.
Most of the cash will be directed toward biotechnology startups developing new drugs, while 20% to 30% of it going toward medical device makers, said Maina Bhaman, one of the firm’s partners. Sofinnova has already funneled cash from the fund into five companies, among them radiopharmaceuticals startup Actithera and inflammatory disease drugmaker Elevara Medicines.
Sofinnova’s raise comes amid a recent influx of capital into biotech venture firms. After a slow start to the...
Today's Sponsors
Today's Sponsor